Difference between revisions of "Giant-cell tumor of bone"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "1 PubMed]" to "1/ PubMed]") |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''") |
||
| (18 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | <span id="BackToTop"></span> | |
| − | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
| − | + | [[#top|Back to Top]] | |
| − | + | </div> | |
| − | + | {{#lst:Editorial board transclusions|sarcoma}} | |
| − | |||
| − | |} | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 12: | Line 10: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
| + | ==NCCN== | ||
| + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer].'' | ||
=All lines of therapy= | =All lines of therapy= | ||
==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}== | ==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}== | ||
| Line 33: | Line 35: | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Denosumab (Xgeva)]] as follows: | *[[Denosumab (Xgeva)]] as follows: | ||
| − | **Cycle 1: 120 mg SC once per day on days 1, 8, 15 | + | **Cycle 1: 120 mg SC once per day on days 1, 8, 15 |
**Cycle 2 onwards: 120 mg SC once on day 1 | **Cycle 2 onwards: 120 mg SC once on day 1 | ||
====Supportive therapy==== | ====Supportive therapy==== | ||
| − | *Calcium 500 mg PO once per day | + | *[[Calcium]] 500 mg PO once per day |
| − | *Vitamin D 400 IU PO once per day | + | *[[Vitamin D]] 400 IU PO once per day |
'''28-day cycles''' | '''28-day cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''Amgen 20040215:''' Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. Epub 2010 Feb 10. [https://doi.org/10.1016/S1470-2045(10)70010-3 link to original article] ''' | + | # '''Amgen 20040215:''' Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. Epub 2010 Feb 10. [https://doi.org/10.1016/S1470-2045(10)70010-3 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20149736/ PubMed] [https://clinicaltrials.gov/study/NCT00396279 NCT00396279] |
| − | # '''Amgen 20062004:''' Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. [https://doi.org/10.1016/S1470-2045(13)70277-8 link to original article] ''' | + | # '''Amgen 20062004:''' Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. [https://doi.org/10.1016/S1470-2045(13)70277-8 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/23867211/ PubMed] [https://clinicaltrials.gov/study/NCT00680992 NCT00680992] |
| − | ## '''Update:''' Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. [https://doi.org/10.1016/S1470-2045(19)30663-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31704134 PubMed] | + | ## '''Update:''' Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. [https://doi.org/10.1016/S1470-2045(19)30663-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31704134/ PubMed] |
[[Category:Giant-cell tumor of bone regimens]] | [[Category:Giant-cell tumor of bone regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Bone sarcomas]] | [[Category:Bone sarcomas]] | ||
Latest revision as of 23:38, 15 July 2024
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Bone Cancer.
All lines of therapy
Denosumab monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Thomas et. al 2010 (Amgen 20040215) | 2006-2008 | Phase 2 (RT) |
| Chawla et al. 2013 (Amgen 20062004) | 2008-2011 | Phase 2 (RT) |
Targeted therapy
- Denosumab (Xgeva) as follows:
- Cycle 1: 120 mg SC once per day on days 1, 8, 15
- Cycle 2 onwards: 120 mg SC once on day 1
Supportive therapy
28-day cycles
References
- Amgen 20040215: Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. Epub 2010 Feb 10. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00396279
- Amgen 20062004: Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00680992
- Update: Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. link to original article PubMed